Compare Amphastar Pharmaceuticals Inc (AMPH) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs KB Financial Group, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while KB Financial Group, Inc. trades at $125 (market cap $42.55B). The key difference: KB Financial Group, Inc. is far larger — about 51.5× Amphastar Pharmaceuticals Inc's market cap, and KB Financial Group, Inc. pays a 2.55% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KB | |
|---|---|---|
Market Cap | $826.08M | $42.55B |
Sector | Health | Financials |
52-Week High | $30.81 | $123.19 |
52-Week Low | $16.87 | $77.50 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
KB Financial Group (KB) trades at $123.19, up 6.78% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals from moving averages, though oscillators suggest caution with RSI near overbought levels. Fundamentally, revenue grew to $21.23T in 2025 with a net income margin of 27.82%, supported by diversification into non-banking segments. Analyst sentiment is mixed with a 33% buy rating, while recent news highlights dividend potential and non-banking growth.
The outlook for KB remains positive due to earnings growth and strategic diversification, but risks include reliance on interest income and macroeconomic sensitivity. Near-term resistance at $121 could limit upside, while support at $112 provides a cushion. Institutional holdings and dividend focus offer stability, yet investors should monitor interest rate impacts and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
